Concepedia

Brenda Cirincione

BC

Statistics

Publications

18

Citations

1.1K

H-Index

16

Active since

2005

Affiliations

University at Buffalo, State University of New York(Current)

Cognizant (United States)

Bristol-Myers Squibb (United States)

Bristol-Myers Squibb (Sweden)

Eli Lilly (United States)

Brenda Cirincione is an author at University at Buffalo, State University of New York specializing in pharmacokinetics, pharmacology, and pharmacy.

Publications per year

2005–2018

18

Publications

18

Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment

Mark Fineman, Kenneth Mace, M. Diamant et al. · Diabetes Obesity and Metabolism · 2012 · 151 citations

, , +14

Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing

Mark Fineman, Shawn Flanagan, Kristin Taylor et al. · Clinical Pharmacokinetics · 2010 · 135 citations

, , +10

Use of Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Phase 2 and 3 Dosing Strategies for Doripenem

Sujata M. Bhavnani, Jeffrey Hammel, Brenda Cirincione et al. · Antimicrobial Agents and Chemotherapy · 2005 · 123 citations

, , +17

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections

Alison Meagher, Julie Passarell, Brenda Cirincione et al. · Antimicrobial Agents and Chemotherapy · 2007 · 114 citations · Full text

, , +16

Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections

Julie Passarell, Alison Meagher, Kathryn Liolios et al. · Antimicrobial Agents and Chemotherapy · 2007 · 106 citations

, , +15

1–5 of 18